Plain-English translation of NCT07136012 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new medication given by injection under the skin, to see if it can help prevent serious heart problems in people who have high levels of a substance called lipoprotein(a) in their blood. Lipoprotein(a) is a type of cholesterol-like particle that can increase your risk of heart attack and stroke. The medication works by lowering this substance, and researchers want to find out whether this actually protects people from having their first major cardiovascular event.
Many people have high lipoprotein(a) levels but don't have good treatment options to lower this risk factor. This trial exists to determine whether this medication can meaningfully prevent heart attacks and other serious cardiac events in this population.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or a placebo (inactive injection), both given as injections under the skin. You would visit the clinic regularly for check-ups, blood tests, and monitoring of your heart health over an extended period. The trial will track whether you experience any heart-related events and measure changes in your lipoprotein(a) levels to see if the medication is working.
AI-generated summary from trial data · Sep 3, 2026 · Not medical advice
United States